Cost and Prescribing Considerations for Biosimilars

Allan Gibofsky, MD; Gary R. Lichtenstein, MD; Peter L. Salgo, MD; Vibeke Strand, MD; and Cole Wilson, PharmD, explain some of the decisions regarding cost and certain prescribing considerations for biosimilars.
July 10, 2017
View Text Version

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars® is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.